• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Thermo Fisher Scientific Partners with Mindray on Clinical Chemistry Analyzers for use with Drugs of Abuse Immunoassays

Share:

February 10, 2021

Thermo Fisher Scientific, the world leader in serving science, today announced a partnership with Mindray, a leading global developer, manufacturer and supplier of medical devices, to make available to customers two clinical chemistry analyzers in the United States (U.S.) and Canada for drug screening in clinical and drug court laboratories.

“Systematically and reliably testing for drugs of abuse is key to helping addicted individuals rehabilitate, ensuring prescribed drugs are not abused and ultimately, helping to combat this crisis,” said Stefan Wolf, president of the clinical diagnostics business at Thermo Fisher Scientific. “Through this exclusive partnership with Mindray we are able to address the needs of our customers in commercial labs, hospitals and the criminal justice field. Now we can better cater to the needs of those laboratories seeking to expand or increase their testing volumes, and laboratories working to consolidate and centralize their testing sites with these two medium- to high-throughput instruments.”

To provide access to drug testing, Thermo Fisher and Mindray have entered into an agreement to offer the FDA-cleared and Health Canada–approved BS-480 (400 tests/hour) and BA-800M (800 tests/hour) analyzers to toxicology labs. Thermo Fisher will also provide an extensive menu of wet lab–validated Thermo Scientific DRI and CEDIA drugs of abuse immunoassay reagents with the instruments to enable the screening of urine samples for the presence of a given drug or a class of drugs.

Taken together, the world-class DRI and CEDIA drugs of abuse immunoassay reagents, validated on Mindray’s instruments, bring a combination of performance and reliability from a single source in a cost-effective, plug-and-play solution. The solution streamlines the drug screening workflow and automates it to reduce risk of human error. The instruments also come with onboard software that has many advanced features, including sample/reagent probe collision protection, sample aggregate detection and a five-minute daily push-button self-service maintenance program.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Thermo Fisher began distributing, installing, training and servicing Mindray BS-480 and BA-800M instruments in the U.S. and Canada last month.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • RCM Myth: Healthcare Billing Is Just A Back-Office JobRCM Myth: Healthcare Billing Is Just A Back-Office Job
  • HealthStream Acquires Providigm to Drive Quality Outcomes via Workforce Training for the Nation’s Skilled Nursing FacilitiesHealthStream Acquires Providigm to Drive Quality Outcomes via Workforce Training for the Nation’s Skilled Nursing Facilities
  • Konica Minolta and Shimadzu Join Forces to Bring Dynamic Digital Radiography to the US Digital Radiography MarketKonica Minolta and Shimadzu Join Forces to Bring Dynamic Digital Radiography to the US Digital Radiography Market
  • Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene TherapyBayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy
  • British Columbia’s Supreme Court approves Canopy Growth, Acreage arrangementBritish Columbia’s Supreme Court approves Canopy Growth, Acreage arrangement
  • Riverside Partners’ Portfolio Company Syner-G Acquires RMCRiverside Partners’ Portfolio Company Syner-G Acquires RMC
  • Philips Unveils Vendor-Neutral Radiology Operations Command Center, Automated Radiology Workflow SuitePhilips Unveils Vendor-Neutral Radiology Operations Command Center, Automated Radiology Workflow Suite
  • Ancient DNA Reveals Yet More Complicated Histories In The AmericasAncient DNA Reveals Yet More Complicated Histories In The Americas

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications